Retrospective, Registry-based, Cohort Investigation of Clinical Outcomes in Patients with Cutaneous Squamous Cell Carcinoma and Basal Cell Carcinoma in Finland

Most cases of keratinocyte cancer can be treated effectively with surgery. However, survival is reduced in patients with advanced disease. This retrospective cohort study evaluated overall survival of patients with invasive keratinocyte cancers, and high-risk features for progression of the disease and mortality in Finnish patients in a real-world setting. A total of 43,143 patients with keratinocyte cancer types of basal cell carcinoma and 10,380 with cutaneous squamous cell carcinoma were identified nationwide. More detailed patient records were available for a subset of patients (basal cell carcinoma n = 5,020 and cutaneous squamous cell carcinoma n = 1,482) from a regional database. Fifty percent of patients with advanced cutaneous squamous cell carcinoma died approximately 4.5 years after diagnosis. Multivariable models suggested that risk factors for keratinocyte cancer progression were male sex, presence of comorbidities, immunosuppression, and pre-cancerous lesions, while risk factors for disease-specific mortality were advanced disease stage with immunosuppression, other malignancies, and consecutive surgical excisions. These results suggest that identifying patient and tumour factors associated with poor disease outcome could be important when determining appropriate treatment and follow-up; however, further studies are necessary.</p

Real-world evidence on multiple myeloma treated in 2013-2019 in the Hospital District of Helsinki and Uusimaa, Finland - Supplementary material

Supplementary figure 1. The annual incidence of stem cell transplantation (SCT) eligible multiple myeloma patients with 95% confidence intervals in 2013–2018 estimated as the number of SCT procedures (only the first SCT procedure per patient considered) among initiated first-line immunochemotherapies in each year. Both incidence per each year (solid line) and mean incidence (dashed line; Mann Kendall trend test p-value, 0.71) are provided.Supplementary figure 2. All-cause health care resource use per patient year (PPY; with 95% confidence intervals) in multiple myeloma patients with and without record(s) on stem cell transplantation (SCT). Patients diagnosed and treated in the Hospital District of Helsinki and Uusimaa, Finland, in 2013–2019 were included.Supplementary figure 3. Cox proportional multivariable hazards models assessing the effect of the patient characteristics (age, sex, and Charlson Comorbidity Index, CCI) at diagnosis and diagnosis year on the overall survival.Supplementary table 1. Multiple myeloma medications and respective codes utilized in the studySupplementary table 2. ICD-10 diagnoses recorded five years prior to the first ICD-10 record on multiple myeloma as a diagnosis, among 509 adult patients diagnosed and treated with immunochemotherapy in 2013–2019 in the Hospital District of Helsinki and Uusimaa, Finland.Supplementary table 3. The number of multiple myeloma patients with each type of induction/reinduction treatment in the first three lines of immunochemotherapy (ICT; for the abbreviations, see the Supplementary table 1). ICTs started in 2013–2016 (“Pre 2017”) and 2017–2019 (“Post 2017”) are separately reportedSupplementary methods</p